vTv’s azeliragon study for Alzheimer’s disease and type 2 diabetes has support but some scepticism remains

vTv Therapeutics’ azeliragon could have an improved chance of success in an ongoing Phase II and planned Phase III for patients with AD and type 2 diabetes. Credit: Maya Kruchankova via Shutterstock.